The Absence Of An Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result In Increased OHE-Related Length Of Stay And Hospitalization-Related Costs Due To OHE Rate Underestimation, According To New Analysis
Portfolio Pulse from Benzinga Newsdesk
Bausch Health Companies Inc. (NYSE:BHC) and its gastroenterology business, Salix Pharmaceuticals, have announced findings from a descriptive analysis of a hospital database showing that the absence of an overt hepatic encephalopathy-specific diagnosis code may have resulted in increased length of stay and hospitalization-related costs. The analysis showed that hospitalizations identified using in-hospital Xifaxan or lactulose use combined with a diagnosis for altered mental status, unspecified encephalopathy, or cirrhosis, had a mean hospital billing charge 2.5 times higher and mean length of stay 2.0 times longer than solely relying on OHE as a primary diagnosis.
November 10, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Bausch Health's analysis reveals that the absence of a specific diagnosis code for overt hepatic encephalopathy may lead to increased hospitalization costs and length of stay. This could potentially impact the company's reputation and demand for its products.
The news directly pertains to Bausch Health and its gastroenterology business, Salix Pharmaceuticals. The findings from their analysis could potentially impact the company's reputation and the demand for its products, especially if the healthcare industry takes these findings into account and changes its practices. However, it's uncertain how this will affect the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100